- Home
- WKSP vs IGC Comparison
WKSP vs IGC Comparison
Compare WKSP & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WKSP
- IGC
- Stock Information
- Founded
- WKSP 2003
- IGC 2005
- Country
- WKSP United States
- IGC United States
- Employees
- WKSP N/A
- IGC N/A
- Industry
- WKSP Auto Parts:O.E.M.
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- WKSP Consumer Discretionary
- IGC Health Care
- Exchange
- WKSP Nasdaq
- IGC Nasdaq
- Market Cap
- WKSP 27.2M
- IGC 29.4M
- IPO Year
- WKSP N/A
- IGC N/A
- Fundamental
- Price
- WKSP $0.82
- IGC $0.34
- Analyst Decision
- WKSP Strong Buy
- IGC Strong Buy
- Analyst Count
- WKSP 1
- IGC 2
- Target Price
- WKSP $2.00
- IGC $3.75
- AVG Volume (30 Days)
- WKSP 1.6M
- IGC 387.6K
- Earning Date
- WKSP 11-13-2024
- IGC 02-12-2025
- Dividend Yield
- WKSP N/A
- IGC N/A
- EPS Growth
- WKSP N/A
- IGC N/A
- EPS
- WKSP N/A
- IGC N/A
- Revenue
- WKSP $6,395,908.00
- IGC $1,183,000.00
- Revenue This Year
- WKSP $424.11
- IGC N/A
- Revenue Next Year
- WKSP $260.82
- IGC $13.38
- P/E Ratio
- WKSP N/A
- IGC N/A
- Revenue Growth
- WKSP 776.97
- IGC N/A
- 52 Week Low
- WKSP $0.36
- IGC $0.27
- 52 Week High
- WKSP $1.54
- IGC $0.91
- Technical
- Relative Strength Index (RSI)
- WKSP 46.71
- IGC 44.69
- Support Level
- WKSP $0.79
- IGC $0.31
- Resistance Level
- WKSP $0.88
- IGC $0.36
- Average True Range (ATR)
- WKSP 0.11
- IGC 0.02
- MACD
- WKSP -0.02
- IGC -0.00
- Stochastic Oscillator
- WKSP 15.33
- IGC 42.71
About WKSP Worksport Ltd.
Worksport Ltd through its subsidiaries, designs, develops, manufactures, and owns the IP on a variety of tonneau covers, solar integrations, and NP (Non-Parasitic), Hydrogen-based true green energy solutions for the sustainable, clean energy, and automotive industries. The company's product includes soft vinyl tonneau covers and hard aluminum tonneau covers.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.